- Home
- BCSF vs HELP Comparison
BCSF vs HELP Comparison
Compare BCSF & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCSF | HELP |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.7M | 862.2M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCSF | HELP |
|---|---|---|
| Price | $11.28 | $9.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $12.63 | ★ $41.56 |
| AVG Volume (30 Days) | 512.0K | ★ 1.5M |
| Earning Date | 11-09-2026 | 11-24-2026 |
| Dividend Yield | ★ 16.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $3.76 |
| 52 Week High | $14.70 | $15.15 |
Technical Indicators
Market Signals| Indicator | BCSF | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 61.17 | 43.23 |
| Support Level | $10.00 | $4.41 |
| Resistance Level | $11.35 | $11.74 |
| Average True Range (ATR) | 0.30 | 0.85 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 91.13 | 39.35 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.